Q-omics provides the consensus-scored OR1F12 profile across patient tissues and cancer cell-line models. OR1F12 expression is associated with patient survival in 18 of 34 cancer types, with the highest sampling consensus in UCEC. Among the 18 cancer types available for tumor–normal comparison, OR1F12 is differentially expressed in 7, with the highest sampling consensus in KIRC. Additionally, OR1F12 RNA expression shows 10,828 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight UCEC, KIRC, and UVM as cancer lineages where OR1F12 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for OR1F12 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes OR1F12 survival associations across molecular data types. OR1F12 RNA expression shows survival associations in the most cancer types (18). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible OR1F12 RNA expression–survival associations across cancer types. High OR1F12 expression shows unfavorable associations in UCEC, but favorable associations in BLCA, LUAD, ACC, LAML and UCS. The UCEC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .002). Together, the overview and detailed table identify UCEC as the clearest survival context for OR1F12 RNA expression.
This table summarizes OR1F12 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for OR1F12. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. OR1F12 shows lower tumor expression in KIRC, THCA, KIRP and KICH and higher tumor expression in CHOL and LIHC. The KIRC box plot shows higher OR1F12 RNA expression in normal versus tumor tissue (log2 FC = −0.083, t-test p < 0.001).
This table shows molecular features associated with OR1F12 in patient tissues and cancer cell lines. In patient samples, OR1F12 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set.
